33852-01-6

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-2-(pyrrolidin-1-yl)pyrimidine is used as a building block for the synthesis of various biologically active molecules, including pharmaceutical drugs, due to its potential antiviral and anticancer properties.
Used in Research Laboratories:
In research settings, 4-chloro-2-(pyrrolidin-1-yl)pyrimidine is utilized for the synthesis of novel chemical compounds, contributing to the advancement of chemical and pharmaceutical research.
Safety Considerations:
Due to its chemical structure and potential reactivity, 4-chloro-2-(pyrrolidin-1-yl)pyrimidine requires handling and usage in accordance with strict safety guidelines to prevent any potential hazards.

Upstream product

• 123-75-1 pyrrolidine 
• 3934-20-1 2,6-Dichloropyrimidine 

Relevant academic research and scientific papers

Synthesis of deuterium labeled 2,4-dipyrrolidinylpyrimidine as a chemical probe for P450 mediated oxidation of tirilazad mesylate

Selective deuterium labelled pyrrolidinylpyrimidine analogs were synthesized to provide a probe for the metabolite identification of Tirilazad. Synthesis of 2-[D8]-pyrrolidinyl-4-pyrrolidinylpyrimidine (1) and 4-[D8]pyrrolidinyl-2-pyrrolidinylpyrimidine (2) was accomplished by reaction of pyrrolidine (3) with 2,4-dichloropyrimidine (4), separation of the two reaction products (5 and 6) and reaction of these products with [D8]pyrrolidine (7). [D16]2,4-dipyrrolidinylpyrimidine (8) was prepared by reaction of [D8]pyrrolidine (7) with 2,4-dichloropyrimidine (4).

Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1

The allosteric modulator 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (PSNCBAM-1, 2) bound the cannabinoid receptor 1 (CB1) and antagonized G protein coupling. This compound demonstrated potent anorectic effects similar to the CB1 antagonist rimonabant that once was marketed for the treatment of obesity, suggesting a new chemical entity for the discovery of antiobesity drugs. To increase structural diversity of this class of CB1 ligands, we designed and synthesized two classes of novel analogues, in which the pyridine ring of 2 was replaced by a pyrimidine ring. These positively modulate the binding of the CB1 orthosteric agonist CP55,940 while exhibiting an antagonism of G-protein coupling activity. Interestingly, compounds 7d and 8d demonstrated ERK1/2 phosphorylation mediated via β-arrestin unlike the orthosteric CP55,940 that does so in a G protein-dependent manner. These can serve as new lead compounds for the future development of CB1 allosteric modulators that show biased agonism and potentially antiobesity behavior via a new mechanism.